Top of this page
Skip navigation, go straight to the content
Welcome to UCB Investor Relations
Our Investor Relations team aim to serve analysts, shareholders and potential investors with timely, valuable and reliable information.
UCB has the potential to become the next generation biopharma leader
- Powerful and unique combination of biology and chemistry research capabilities
- 11 large and small molecules in clinical development, spanning 13 different types of diseases
- A track record of turning novel ideas into therapeutic and commercial realities
- Solid product life-cycle management
Lorem
Contact our IR team
Quick access IR
Upcoming Events
- UCB and Biogen Idec discontinue Phase II clinical trial of CDP323 30-Jun-2009
- UCB brings Neupro® back to all patients in Europe 29-Jun-2009
- Cimzia®, the only PEGylated anti-TNF, recommended for approval in the EU for rheumatoid arthritis 26-Jun-2009
- Jazz Pharmaceuticals and UCB announce second Phase III study of sodium oxybate in patients with fibromyalgia meets primary endpoints 24-Jun-2009
